CV 6504

Drug Profile

CV 6504

Latest Information Update: 03 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Nonindustrial source; Takeda
  • Class Antineoplastics
  • Mechanism of Action 5-lipoxygenase inhibitors; Oxygen radical scavengers; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Nephritis; Pancreatic cancer

Most Recent Events

  • 07 Dec 2000 Phase-II clinical trials for Pancreatic cancer in England (Unknown route)
  • 07 Dec 2000 A phase II study has been added to the Cancer therapeutic trials and pharmacokinetics sections
  • 11 Oct 2000 Discontinued-Preclinical for Cancer in England (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top